Special Interest Programs

Endocrine Nurses Symposium
ENS Poster Session and Cocktail Reception
Wyeth Scientific Exhibit Poster Session
Women in Endocrinology Dinner
Corporate Liaison Board Forum
Increasing Minority Involvement in Clinical Research
Increasing Minority Involvement in Clinical Research Dinner
5th Annual Cardiovascular Endocrinology Dinner Symposium
TSEC: Where knowledge and innovation intersect

ENS Poster Session and Cocktail Reception
Saturday, June 2, 2007
5:30-7:30 PM
Westin Harbour Castle Hotel
Regatta Ballroom

Wyeth Scientific Exhibit Poster Session
Monday, June 4, 2007
6:30-9:30 PM
Westin Harbour Castle Hotel
Harbour Ballroom

Women in Endocrinology Dinner
Saturday, June 2
6:30-10:00 PM
Westin Harbour Castle Hotel
Harbor Ballroom
Contact: (for special dietary requests or for more information)
Julie Sharpless, at 919-966-1254 or julie_sharpless@cceb.med.upenn.edu.

Corporate Liaison Board Forum
Saturday, June 2
6:30 - 9:30 PM
Fairmont Royal York; Concert Hall Ballroom

The Forum, hosted by the Corporate Liaison Board, will focus on novel targets for diagnosis and treatment of Endocrine Neoplasia with speakers from industry, academia, and government discussing new technologies, biomarkers and targeted molecular therapies.

Objectives:

To discuss the utility of currently available somatostatin analogs in treating secretion and proliferation of endocrine tumors
To discuss the theoretical considerations in devising new therapies utilizing somatostatin analogs
To demonstrate that multiplicity in hereditary endocrine tumors will sometimes require management different than for common variety tumors
To demonstrate that gene testing can assist in the prevention of hereditary endocrine cancer. It guides the most effective strategy if a cancer target organ (as the thyroid in MEN2) can be ablated without much morbidity
To distinguish patients with advanced thyroid cancer who can be monitored from those who should be considered for advanced therapy including clinical trials
To appreciate mechanisms behind novel therapies being considered and tested in patients with advanced thyroid cancer

Novel Targets for Diagnosis and Treatment of Endocrine Neoplasia

Introductory Remarks: Campbell P. Howard, MD, NovoNordisk, Program Director
Therapeutic Utility of Somatostatin Analogs in Endocrine Neoplasia, Michael Culler, MS, PhD, Endocrinology Research, IPSEN
Multiple Endocrine Neoplasia Type 1: Targeting the Humors & Tumors, Stephen Marx, MD, Metabolic Dis Branch, NIDDK/NIH
Nuclear Hormone Receptors as Targeted Therapy in Thyroid Cancer, Bryan Haugen, MD, Univ of Colorado Hlth Sci Ctr

Contact: Nancy Chill at nchill@endo-society.org

Increasing Minority Involvement in Clinical Research Symposium
Saturday, June 2
9:30 - 11:00 AM
Metro Toronto Convention Centre
(Supported by a grant from the Robert Wood Johnson Foundation)

Due to mounting evidence of ethnicity-specific differences in both the response to certain therapeutics and the reliability of risk markers in predicting disease, stakeholders in academia, industry, and government all recognize that eliminating disparities in clinical trial participation is a priority.

The Endocrine Society, through a grant from the Robert Wood Johnson Foundation, is developing a set of recommendations for increasing involvement of minorities in clinical research. The recommendations are directed toward US Congress, regulatory agencies, funding agencies, and academic institutions and address the problem from the perspectives of:

The research volunteer and community leaders who play a key role in education and public acceptance;
the researchers (pharmaceutical and academic); and
government/regulatory agencies that fund and/or oversee clinical trials.

The recommendations were developed by a task force of individuals—both Society members and non-member experts—from the above-mentioned stakeholder groups, including community leaders, researchers, and administrators. Their work builds on an initial session at ENDO 06 in which several speakers shared their experiences with implementing statistically powerful and diverse clinical investigations in the academic and corporate settings.

This official ENDO 07 symposium will feature the following speakers and presentations:

"Increasing Awareness of Gender and Ethnic Disparities among Clinical Investigators"
Kenneth A. Getz, M.B.A.; Senior Research Fellow; Senior Fellow, Tufts CSDD; Chairman, CISCRP

"Eliminating Racial and Ethnic Disparities among Clinical Investigators"
Alfonso Alanis, MD; CEO, Anaclim, a minority-focused contract research organization

"Eliminating Health Disparities—Increasing Recruitment of Racial and Ethnic Minorities to Clinical Trials: Federal Government Initiatives"
Lawrence Agodoa, MD; Director, Office of Minority Health Research Coordination, NIDDK

Increasing Minority Involvement in Clinical Research Dinner
Saturday, June 2
6:30 - 9:00 PM
Fairmont Royal York

The Endocrine Society invites you to attend a dinner and panel-led discussion on issues related to minority involvement in clinical research. The Society’s recommendations will be discussed, and the panel will include:

Alfonso Alanis, MD, former executive of Eli Lilly & Co. and the majority founding partner of Anaclim, a new contract research organization
Robert W. Harrison, III, MD, professor of medicine, emeritus, University of Rochester School of Medicine, Rochester, NY
Larry Agodoa, MD, director of the Office of Minority Health Research Coordination at the National Institutes of Health-National Institutes of Diabetes and Digestive and Kidney Diseases
Brian Gibbs, PhD, senior research scientist in the Department of Health Policy and Management at the Harvard School of Public Health and director of Cherishing Our Hearts and Souls
Rhonda Bentley-Lewis, MBA, MD, instructor of medicine in the Endocrinology, Diabetes, and Hypertension Division of Brigham and Women’s Hospital

The discussions are designed to be lively, wide-ranging, and informative, and attendees will have the opportunity to ask questions of the panel and to share their experiences with the panel and with fellow attendees.

Please RSVP for this event by May 11, 2007. For additional information and to RSVP, please contact Stacey Trunnell at 240-482-1389 or strunnell@endo-society.org.

5th Annual Cardiovascular Endocrinology Dinner Symposium
Cardiovascular Endocrinology: New Therapeutic Approaches to Cardiovascular Disease Prevention
Monday, June 4, 7:00-9:00 PM
Fairmont Royal York Hotel
Ontario Room
Registration Fee: $50
(Supported by GlaxoSmithKline Pharmaceuticals, Inc.)

The Cardiovascular Endocrinology Dinner Symposium will be hosted by Dr. Ellen Seely and Dr. Robert Carey. All ENDO 2007 registrants with an interest in cardiovascular endocrinology are encouraged to attend. To register, check the appropriate box on the Registration Form. Limited to 200 registrants.

ACEIs and ARBs are very successful: Why should weadd renin inhibitors?, Norman Hollenberg, MD PhD
Cardiovascular complications of aldosterone excess and resistant hypertension, David Calhoun, MD

TSEC: Where knowledge and innovation intersect
Scientific Exhibit Poster Reception
(non-CME event)
Monday, June 4, 2007; 6:30 PM to 9:30 PM
Westin Harbour Castle Hotel
Harbour Ballroom
(Supported by Wyeth)

After years of research and development, Wyeth is proud to have the opportunity to introduce new data on Tissue Selective Estrogen Complex (TSEC).

For the first time, Wyeth will be displaying important preclinical and clinical data, including Phase III findings about TSEC, an exciting new development in women's health. Join us for discussion and refreshments with investigators.


Search Program-at-a-Glance Highlights Basic Science Clinical Science & Practice Pre-Conference Workshops Itinerary Planner Pre-Conference Workshops Special Events Special Interest Programs Satellite Meetings	Special Interest Programs Endocrine Nurses Symposium ENS Poster Session and Cocktail Reception Wyeth Scientific Exhibit Poster Session Women in Endocrinology Dinner Corporate Liaison Board Forum Increasing Minority Involvement in Clinical Research Increasing Minority Involvement in Clinical Research Dinner 5th Annual Cardiovascular Endocrinology Dinner Symposium TSEC: Where knowledge and innovation intersect ENS Poster Session and Cocktail Reception Saturday, June 2, 2007 5:30-7:30 PM Westin Harbour Castle Hotel Regatta Ballroom Wyeth Scientific Exhibit Poster Session Monday, June 4, 2007 6:30-9:30 PM Westin Harbour Castle Hotel Harbour Ballroom Women in Endocrinology Dinner Saturday, June 2 6:30-10:00 PM Westin Harbour Castle Hotel Harbor Ballroom Contact: (for special dietary requests or for more information) Julie Sharpless, at 919-966-1254 or julie_sharpless@cceb.med.upenn.edu. Corporate Liaison Board Forum Saturday, June 2 6:30 - 9:30 PM Fairmont Royal York; Concert Hall Ballroom The Forum, hosted by the Corporate Liaison Board, will focus on novel targets for diagnosis and treatment of Endocrine Neoplasia with speakers from industry, academia, and government discussing new technologies, biomarkers and targeted molecular therapies. Objectives: To discuss the utility of currently available somatostatin analogs in treating secretion and proliferation of endocrine tumors To discuss the theoretical considerations in devising new therapies utilizing somatostatin analogs To demonstrate that multiplicity in hereditary endocrine tumors will sometimes require management different than for common variety tumors To demonstrate that gene testing can assist in the prevention of hereditary endocrine cancer. It guides the most effective strategy if a cancer target organ (as the thyroid in MEN2) can be ablated without much morbidity To distinguish patients with advanced thyroid cancer who can be monitored from those who should be considered for advanced therapy including clinical trials To appreciate mechanisms behind novel therapies being considered and tested in patients with advanced thyroid cancer Novel Targets for Diagnosis and Treatment of Endocrine Neoplasia Introductory Remarks: Campbell P. Howard, MD, NovoNordisk, Program Director Therapeutic Utility of Somatostatin Analogs in Endocrine Neoplasia, Michael Culler, MS, PhD, Endocrinology Research, IPSEN Multiple Endocrine Neoplasia Type 1: Targeting the Humors & Tumors, Stephen Marx, MD, Metabolic Dis Branch, NIDDK/NIH Nuclear Hormone Receptors as Targeted Therapy in Thyroid Cancer, Bryan Haugen, MD, Univ of Colorado Hlth Sci Ctr Contact: Nancy Chill at nchill@endo-society.org Increasing Minority Involvement in Clinical Research Symposium Saturday, June 2 9:30 - 11:00 AM Metro Toronto Convention Centre (Supported by a grant from the Robert Wood Johnson Foundation) Due to mounting evidence of ethnicity-specific differences in both the response to certain therapeutics and the reliability of risk markers in predicting disease, stakeholders in academia, industry, and government all recognize that eliminating disparities in clinical trial participation is a priority. The Endocrine Society, through a grant from the Robert Wood Johnson Foundation, is developing a set of recommendations for increasing involvement of minorities in clinical research. The recommendations are directed toward US Congress, regulatory agencies, funding agencies, and academic institutions and address the problem from the perspectives of: The research volunteer and community leaders who play a key role in education and public acceptance; the researchers (pharmaceutical and academic); and government/regulatory agencies that fund and/or oversee clinical trials. The recommendations were developed by a task force of individuals—both Society members and non-member experts—from the above-mentioned stakeholder groups, including community leaders, researchers, and administrators. Their work builds on an initial session at ENDO 06 in which several speakers shared their experiences with implementing statistically powerful and diverse clinical investigations in the academic and corporate settings. This official ENDO 07 symposium will feature the following speakers and presentations: "Increasing Awareness of Gender and Ethnic Disparities among Clinical Investigators" Kenneth A. Getz, M.B.A.; Senior Research Fellow; Senior Fellow, Tufts CSDD; Chairman, CISCRP "Eliminating Racial and Ethnic Disparities among Clinical Investigators" Alfonso Alanis, MD; CEO, Anaclim, a minority-focused contract research organization "Eliminating Health Disparities—Increasing Recruitment of Racial and Ethnic Minorities to Clinical Trials: Federal Government Initiatives" Lawrence Agodoa, MD; Director, Office of Minority Health Research Coordination, NIDDK Increasing Minority Involvement in Clinical Research Dinner Saturday, June 2 6:30 - 9:00 PM Fairmont Royal York The Endocrine Society invites you to attend a dinner and panel-led discussion on issues related to minority involvement in clinical research. The Society’s recommendations will be discussed, and the panel will include: Alfonso Alanis, MD, former executive of Eli Lilly & Co. and the majority founding partner of Anaclim, a new contract research organization Robert W. Harrison, III, MD, professor of medicine, emeritus, University of Rochester School of Medicine, Rochester, NY Larry Agodoa, MD, director of the Office of Minority Health Research Coordination at the National Institutes of Health-National Institutes of Diabetes and Digestive and Kidney Diseases Brian Gibbs, PhD, senior research scientist in the Department of Health Policy and Management at the Harvard School of Public Health and director of Cherishing Our Hearts and Souls Rhonda Bentley-Lewis, MBA, MD, instructor of medicine in the Endocrinology, Diabetes, and Hypertension Division of Brigham and Women’s Hospital The discussions are designed to be lively, wide-ranging, and informative, and attendees will have the opportunity to ask questions of the panel and to share their experiences with the panel and with fellow attendees. Please RSVP for this event by May 11, 2007. For additional information and to RSVP, please contact Stacey Trunnell at 240-482-1389 or strunnell@endo-society.org. 5th Annual Cardiovascular Endocrinology Dinner Symposium Cardiovascular Endocrinology: New Therapeutic Approaches to Cardiovascular Disease Prevention Monday, June 4, 7:00-9:00 PM Fairmont Royal York Hotel Ontario Room Registration Fee: $50 (Supported by GlaxoSmithKline Pharmaceuticals, Inc.) The Cardiovascular Endocrinology Dinner Symposium will be hosted by Dr. Ellen Seely and Dr. Robert Carey. All ENDO 2007 registrants with an interest in cardiovascular endocrinology are encouraged to attend. To register, check the appropriate box on the Registration Form. Limited to 200 registrants. ACEIs and ARBs are very successful: Why should weadd renin inhibitors?, Norman Hollenberg, MD PhD Cardiovascular complications of aldosterone excess and resistant hypertension, David Calhoun, MD TSEC: Where knowledge and innovation intersect Scientific Exhibit Poster Reception (non-CME event) Monday, June 4, 2007; 6:30 PM to 9:30 PM Westin Harbour Castle Hotel Harbour Ballroom (Supported by Wyeth) After years of research and development, Wyeth is proud to have the opportunity to introduce new data on Tissue Selective Estrogen Complex (TSEC). For the first time, Wyeth will be displaying important preclinical and clinical data, including Phase III findings about TSEC, an exciting new development in women's health. Join us for discussion and refreshments with investigators.
About \| CME \| Media \| Contact Copyright 2006 - The Endocrine Society 8401 Connecticut Ave. \| Suite 900 \| Chevy Chase, MD 20815-5817 Tel: 888.363.6274 \| Fax: 301.941.0259 \| Email: societyservices@endo-society.org